REVIEW article
Front. Oncol.
Sec. Radiation Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1583168
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
Provisionally accepted
- 1Dana–Farber Cancer Institute, Boston, Massachusetts, United States
- 2University of California, Los Angeles, California, United States
- 3University of New South Wales, Sidney, Australia
- 4City of Hope National Medical Center, Duarte, United States
- 5MD Anderson Cancer Center, Houston, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [ 177 Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patients respond optimally to this treatment; even measuring response accurately can be difficult. Moreover, there is currently a lack of validated prognostic and predictive biomarkers for [ 177 Lu]Lu-PSMA-617 treatment in this patient population. There is, therefore, a growing need to identify biomarkers to help optimize patient selection for [ 177 Lu]Lu-PSMA-617 and guide therapy decisionmaking. This review explores the landscape of emerging clinical, molecular, and imaging biomarkers, and their potential utility as prognostic and/or predictive biomarkers in the context of [ 177 Lu]Lu-PSMA-617 treatment for patients with mCRPC.
Keywords: metastatic castration-resistant prostate cancer, prostate-specific membrane antigen, Radioligand Therapy, [177Lu]Lu-PSMA-617, biomarkers
Received: 25 Feb 2025; Accepted: 11 Jun 2025.
Copyright: © 2025 Beltran, Calais, Emmett, Kuo and Logothetis. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Phillip H. Kuo, City of Hope National Medical Center, Duarte, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.